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MaBACKGROUND TheRELAX (Phosphodiesterase-5 Inhibition to ImproveClinicalStatusandExerciseCapacity inHeartFailure
with Preserved Ejection Fraction) study was a multicenter, randomized trial of sildenaﬁl versus placebo in heart failure with
preserved ejection fraction (HFpEF) with rigorous entry criteria and extensive phenotypic characterization of participants.
OBJECTIVES The aim of this study was to characterize clinical features, exercise capacity, and outcomes in patients
with HFpEF with or without diabetes and gain insight into contributing pathophysiological mechanisms.
METHODS The RELAX study enrolled 216 stable outpatients with heart failure, an ejection fraction$50%, increased
natriuretic peptide or intracardiac pressures, and reduced exercise capacity. Prospectively collected data included echocar-
diography, cardiacmagnetic resonance, a comprehensivebiomarker panel, exercise testing,andclinical eventsover6months.
RESULTS Compared with nondiabetic patients (n ¼ 123), diabetic HFpEF patients (n ¼ 93) were younger, more obese,
and more often male and had a higher prevalence of hypertension, renal dysfunction, pulmonary disease, and vascular
disease (p < 0.05 for all). Uric acid, C-reactive protein, galectin-3, carboxy-terminal telopeptide of collagen type I, and
endothelin-1 levels were higher in diabetic patients (p < 0.05 for all). Diabetic patients had more ventricular hyper-
trophy, but systolic and diastolic ventricular function parameters were similar in diabetic and nondiabetic patients except
for a trend toward higher ﬁlling pressures (E/e0) in diabetic patients. Diabetic patients had worse maximal (peak oxygen
uptake) and submaximal (6-min walk distance) exercise capacity (p < 0.01 for both). Diabetic patients were more likely to
have been hospitalized for heart failure in the year before study entry (47% vs. 28%, p ¼ 0.004) and had a higher
incidence of cardiac or renal hospitalization at 6 months after enrollment (23.7% vs. 4.9%, p < 0.001).
CONCLUSIONS HFpEF patients with diabetes are at increased risk of hospitalization and have reduced exercise capacity.
Multimorbidity, impaired chronotropic reserve, left ventricular hypertrophy, and activation of inﬂammatory, pro-oxidative,
vasoconstrictor, andproﬁbrotic pathwaysmay contribute to adverse outcomes inHFpEF patientswith diabetes. (Evaluating
the Effectiveness of Sildenaﬁl at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure
[The RELAX Study]; NCT00763867) (J Am Coll Cardiol 2014;64:541–9) © 2014 by the American College of
Cardiology Foundation.m the *Washington University School of Medicine, St. Louis, Missouri; yDuke University School of Medicine, Durham, North
rolina; zHarvard University School of Medicine, Boston, Massachusetts; and the xMayo Clinic, Rochester, Minnesota. This study
s supported byNational Institutes of Health grants U10HL084904 (data coordinating center), U10HL084907 (to Dr. Redﬁeld), and
0HL110309 (to Drs. Dávila-Román, Mann, de las Fuentes, Joseph, and Vader). Dr. Lindman was supported by K23 HL116660 and
shington University Institute of Clinical and Translational Sciences grants UL1 TR000448 and KL2 TR000450 from the National
nter for Advancing Translational Sciences of the National Institutes of Health. Dr. Dávila-Román was supported in part by the
rnes-Jewish Hospital Foundation. Dr. Lindman is a consultant for Gerson Lehrman Group Research; and has received research
pport fromBGMedicineandRocheDiagnostics.Dr.Hernandezhasﬁnancial relationshipswithBristol-MyersSquibb,Novartis, and
xoSmithKline in the form of research grants to his institution. All other authors have reported that they have no relationships
evant to the contents of this paper to disclose.
ten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.
u can also listen to this issue’s audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.
nuscript received March 13, 2014; revised manuscript received May 6, 2014, accepted May 19, 2014.
ABBR EV I A T I ON S
AND ACRONYMS
BSA = body surface area
CITP = carboxy-terminal
telopeptide of collagen type I
CMR = cardiac magnetic
resonance
CSA = cross-sectional area
EF = ejection fraction
HFN = Heart Failure Network
HFpEF = heart failure with
preserved ejection fraction
HR = heart rate
hs-cTnI = high-sensitivity
cardiac troponin I
LV = left ventricular
mFS = midwall fractional
shortening
NT-proBNP = N-terminal
pro–B-type natriuretic peptide
NYHA = New York Heart
Association
VO2 = oxygen uptake
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542D iabetes adversely affects outcomesof all types of cardiovascular dis-eases (1). In particular, diabetes is
associated with a 70% to 80% increase in mor-
tality and hospitalizations in patients with
heart failure with preserved ejection fraction
(HFpEF) (2–4), but the underlying mecha-
nisms of this relationship are unclear. Few
studies provide detailed phenotypic compari-
son of diabetic and nondiabetic patients with
HFpEF. Notably, although improving exercise
capacity is an important treatment goal and
common endpoint in clinical trials in HFpEF,
the impact of diabetes on exercise capacity
and the pathophysiological mechanisms driv-
ing such differences have not been evaluated
in patients with HFpEF (5,6). Because 30%
to 40% of patients with HFpEF have diabe-
tes (2,5,7), understanding whether diabetic
HFpEF patients have distinctive character-
istics and outcomes may have important
implications for clinical management and
identiﬁcation of effective medical therapies
for this large patient subgroup.SEE PAGE 550The RELAX (Phosphodiesterase-5 Inhibition to
Improve Clinical Status and Exercise Capacity in
Heart Failure with Preserved Ejection Fraction) study
enrolled both diabetic and nondiabetic patients with
HFpEF (5). This rigorously characterized HFpEF
cohort, including detailed measurements of exercise
capacity, provides the opportunity to evaluate the
diabetic HFpEF phenotype. We hypothesized that
HFpEF patients with diabetes represent a subgroup
with more severe disease with a more severe reduc-
tion in exercise capacity, in association with evidence
of distinctive pathophysiological mechanisms.
METHODS
PATIENT POPULATION. The rationale, design, in-
clusion and exclusion criteria, and primary results
of RELAX have been reported (5,8). RELAX was a
multicenter, randomized 24-week trial of sildenaﬁl
versus placebo in 216 stable outpatients with heart
failure. Patients were eligible for enrollment if they
had an ejection fraction (EF) $50%, New York Heart
Association (NYHA) functional class II to IV symp-
toms, stable medical therapy, and objective evidence
of heart failure. Patients also had to meet 2 screening
criteria: peak oxygen uptake (VO2) #60% of age- and
sex-adjusted normal value (with a respiratory ex-
change ratio $1.0) (9) and either elevated N-terminalpro–B-type natriuretic peptide (NT-proBNP) $400
pg/ml or B-type natriuretic peptide $200 pg/ml) or
elevated pulmonary capillary wedge pressure (rest
>20 mm Hg or exertional >25 mm Hg). The enrolling
sites determined the diagnosis of diabetes and other
clinical characteristics. The institutional review
board at each enrolling site approved the study
protocol, and all patients provided written informed
consent.
STUDY PROCEDURES. Baseline testing included a
history and physical examination, phlebotomy for
biomarkers, Minnesota Living with Heart Failure
Questionnaire, measurement of 6-min walk distance,
echocardiogram, cardiac magnetic resonance (CMR)
(for those in sinus rhythm), and cardiopulmonary
exercise testing.
BIOMARKER ASSESSMENT. Assays were performed at
the Heart Failure Network (HFN) biomarker core lab-
oratory (University of Vermont, Burlington, Vermont)
and included measures of renal function (creatinine
and cystatin-C), markers of neurohumoral activation
(NT-proBNP, endothelin-1, and aldosterone), ﬁbrosis-
related markers (amino-terminal propeptide of pro-
collagen type III, galectin-3, and carboxy-terminal
telopeptide of collagen type I [CITP]), and markers of
myocardial necrosis (high-sensitivity cardiac troponin
I [hs-cTnI]), oxidative stress (uric acid), and inﬂam-
mation (C-reactive protein).
DOPPLER ECHOCARDIOGRAPHY. Brachial blood
pressure and heart rate (HR) were measured while the
echocardiogram was being recorded. Left ventricular
(LV) cavity dimension and wall thicknesses were
measured from 2-dimensional images. LV mass was
calculated using the formula recommended by the
American Society of Echocardiography and indexed
to height1.7 (10,11). Reported EF preferentially used
biplane Simpson’s method, modiﬁed Quinones for-
mula, or single-plane volumetric or visual estimate
(10). Midwall fractional shortening (mFS) and end-
systolic wall stress (circumferential end-systolic
stress) were measured as previously described (12).
Contractility (stress corrected-mFS) was assessed by
indexing mFS to (log-transformed) circumferential
end-systolic stress. Stroke volume was calculated
from the time velocity integral of the pulsed wave
Doppler signal of LV outﬂow tract ﬂow and area.
Pulmonary artery systolic pressure was calculated
from the peak tricuspid regurgitant velocity and the
estimated right atrial pressure using the simpliﬁed
Bernoulli equation. Early diastolic medial and lateral
mitral annular tissue velocity (e0), early mitral inﬂow
deceleration time, and the ratio of the early transmitral
ﬂow velocity (E) to e0 (E/e0) were used to estimate
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543LV relaxation, LV stiffness, and LV ﬁlling pres-
sure, respectively. Pulse pressure and mean arterial
pressure were calculated using standard formulas.
End-systolic pressure was estimated as 0.9  systolic
blood pressure (13). Effective arterial elastance (end-
systolic pressure/stroke volume), systemic arterial
compliance (stroke volume/pulse pressure) and sys-
temic vascular resistance (mean arterial pressure/
cardiac output  80) were derived as previously
described (13). The HFN core echocardiography labo-
ratory (Mayo Clinic, Rochester, Minnesota) completed
all measurements according to the American Society
of Echocardiography recommendations (10,14).
CARDIAC MAGNETIC RESONANCE. Brachial blood
pressure and HR were measured during CMR. Aortic
distensibility was measured using aortic maximal
cross-sectional area (CSAmax) and minimal CSA
(CSAmin) as (aortic CSAmax  aortic CSAmin)/(aortic
CSAmin  pulse pressure) (15). Calculation of volumes
and mass was performed according to Simpson’s
rule on traced endocardial and epicardial short-axis
LV images by the HFN core CMR laboratory (Duke
University, Durham, North Carolina).
CARDIOPULMONARY EXERCISE TESTING. A detailed
description of the RELAX cardiopulmonary exercise
testing protocol, methodologies, and calculations has
been published (5,8). All measurements were per-
formed by the HFN core cardiopulmonary exercise
testing laboratory (Harvard University, Cambridge,
Massachusetts).
STATISTICAL ANALYSIS. Data are reported asmedian
(25th, 75th percentiles) or frequency (%) as appro-
priate. Between-group comparisons used Wilcoxon
rank and chi-square tests. Linear regression models
were used to evaluate the relationship between dia-
betes and peak VO2 or 6-min walk distance, adjusting
for factors known to inﬂuence exercise capacity in
other studies and in the RELAX study (exercise
modality, age, sex, body size, chronotropic response,
and hemoglobin) (16). Chronotropic incompetence
was determined as described previously and chrono-
tropic index ¼ (peak HR  resting HR)/[(220  age) 
resting HR] (17). The association between diabetes and
hospitalization ($1 hospitalizations) for cardiovascu-
lar or renal causes during the 6-month study period
was assessed by a chi-square test and a multivariable
Cox proportional hazards model adjusted for known
predictors (age, NYHA functional class, and glomerular
ﬁltration rate) of hospitalization in patients with
heart failure. We assessed for a potential interaction
between diabetes status and treatment group (silden-
aﬁl vs. placebo) with respect to change (from baseline
to 24 weeks) in peak VO2 and 6-min walk distance,and the number of patients with $1 hospitaliza-
tions during the study period using linear or logistic
regression as appropriate. A p value #0.05 was
considered signiﬁcant for all analyses. All statistical
analyses were performed with SAS software, version
9.2 (SAS Institute, Cary, North Carolina).
RESULTS
CLINICAL CHARACTERISTICS. Of the 216 patients
with HFpEF enrolled in the RELAX study, there
were 93 (43%) with diabetes. Compared with nondia-
betic patients, diabetic patients were younger, more
obese, and more often male and had a higher pre-
valence of comorbidities, including hypertension,
ischemic heart disease, peripheral vascular disease,
and obstructive lung disease (Table 1). Anemia tended
to be more common in diabetic patients, and renal
function was more impaired in diabetic patients with
higher creatinine and cystatin-C levels and lower
estimated glomerular ﬁltration rate. At study entry,
heart failure signs and symptoms and heart failure–
related quality of life were similar between the
groups. Diabetic patients were more often taking cal-
cium channel blockers, statins, and diuretics, but
there was no difference in the use of beta-blockers,
angiotensin-converting enzyme inhibitors, or angio-
tensin receptor blockers. Most patients with diabetes
were taking insulin or oral agents for glycemic control.
BIOMARKER PROFILE. HFpEF patients with or with-
out diabetes had similar increase in NT-proBNP, but
diabetic patients had higher levels of endothelin-1,
a potent endogenous vasoconstrictor (Table 2).
With respect to proﬁbrotic markers, diabetic patients
had higher galectin-3 and CITP levels, but increases
in amino-terminal propeptide of procollagen type III
did not achieve statistical signiﬁcance. Diabetic pa-
tients had higher levels of uric acid and C-reactive
protein, suggesting greater oxidative stress and
inﬂammation, as well as a trend toward higher
levels of hs-cTnI, suggesting more ongoing myocar-
dial necrosis.
VENTRICULAR AND VASCULAR REMODELING AND
FUNCTION. By echocardiography, LV mass index
tended to be higher in diabetic patients, but relative
wall thickness was similar in diabetic and nondiabetic
patients (Table 3). Unadjusted LV cavity dimensions
were similar, but LV end-diastolic dimension was
smaller in diabetic patients when indexed for body
surface area (BSA). Systolic performance was similar
in diabetic and nondiabetic patients. Most diastolic
function parameters were similar in diabetic and
nondiabetic patients, although diabetic patients ten-
ded to have higher E/e0, suggesting higher LV ﬁlling
TABLE 2 Biomarker Proﬁle of HFpEF Patients With and
Without Diabetes
Biomarkers
(Core Laboratory)
Non-DM
(n ¼ 123)
DM
(n ¼ 93) p Value
NT-proBNP 713 (303, 1593) 648 (280, 1553) 0.73
cGMP 77 (58, 102) 79 (56, 101) 0.99
Endothelin-1 2.3 (1.8, 3.0) 2.5 (2.0, 3.5) 0.05
Aldosterone 182 (122, 286) 202 (117, 274) 0.97
PIIINP 7.5 (6.1, 8.9) 8.2 (6.0, 10.9) 0.11
Galectin-3 13.1 (10.6, 16.0) 15.5 (12.2, 21.4) <0.001
CITP 5.7 (4.5, 7.5) 7.8 (5.5, 12.4) <0.001
Uric acid 6.8 (5.5, 8.5) 7.8 (6.3, 9.4) 0.005
C-reactive protein 3.3 (1.6, 7.3) 4.5 (2.1, 10.0) 0.015
hs-cTnI 8.3 (4.7, 16.5) 10.6 (6.5, 20.9) 0.10
Values are median (25th, 75th percentiles).
CITP ¼ carboxy-terminal telopeptide of collagen type I; cGMP ¼ cyclic guano-
sine monophosphate; DM ¼ diabetes mellitus; hs-cTnI ¼ high sensitivity cardiac
troponin I; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; PIIINP ¼
amino-terminal propeptide of procollagen type III.
TABLE 1 Baseline Characteristics of HFpEF Patients With and Without Diabetes
Demographic/Clinical Characteristics
Non-DM
(n ¼ 123)
DM
(n ¼ 93) p Value
Age, yrs 71 (63, 79) 66 (62, 73) 0.003
Female 57.7 35.5 0.001
Self-reported white race 93.5 88.2 0.17
Body surface area, m2 2.02 (1.86, 2.21) 2.23 (2.06, 2.47) <0.001
Body mass index, kg/m2 30.7 (27.6, 34.2) 37.1 (32.3, 42.0) <0.001
Heart rate, beats/min 68 (61, 78) 70 (62, 78) 0.74
Systolic blood pressure, mm Hg 126 (113, 138) 128 (114, 137) 0.97
Comorbidities
Ischemic heart disease 33 47 0.03
Hypertension 77 95 <0.001
Peripheral vascular disease 7 25 <0.001
Obstructive lung disease 12 29 0.002
Hyperlipidemia 70 80 0.11
Atrial ﬁbrillation or ﬂutter 55 46 0.19
Anemia* 30 42 0.06
Hemoglobin, g/dl 13.0 (12.1, 14.0) 12.8 (11.7, 13.7) 0.10
Blood urea nitrogen, mg/dl 22 (16, 25) 28 (20, 39) 0.001
Creatinine 1.05 (0.83, 1.29) 1.21 (0.89, 1.70) <0.001
Glomerular ﬁltration rate, ml/min/1.73 m2 67.5 (51.1, 83.6) 57.1 (39.2, 78.9) 0.02
Cystatin C 1.19 (1.03, 1.55) 1.59 (1.14, 1.97) <0.001
Heart failure
Jugular venous pressure $8 cm 47 44 0.68
Edema 16 26 0.09
NYHA functional class 0.34
II 50 43
III 50 57
MLHFQ total score 42 (30, 58) 47 (26, 68) 0.20
Medications at enrollment
Beta-blocker 76 76 0.90
ACE-I or ARB 67 75 0.17
Aldosterone antagonist 11 11 0.97
Calcium channel blocker 24 40 0.01
Statin 54 76 <0.001
Loop diuretic 72 83 0.07
Any diuretic 82 91 0.046
Diabetes therapy
Insulin treated — 42 —
Oral medications alone — 47 —
Diet alone — 11 —
Values are median (25th, 75th percentiles) or %. *Hemoglobin <13 g/dl for men, <12 g/dl for women.
ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; DM ¼ diabetes
mellitus; MLHFQ ¼ Minnesota Living with Heart Failure Questionnaire; NYHA ¼ New York Heart Association.
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544pressures. Although unadjusted left atrial volumes
were similar, left atrial volume indexed to BSA was
smaller in diabetic patients. Echocardiographic mea-
surements of pulmonary and systemic vascular func-
tion were similar in diabetic and nondiabetic patients.
In the subgroup of patients who underwent
CMR (n ¼ 117), indexed LV mass was higher in
diabetic than nondiabetic patients, whereas LV vol-
umes (indexed to BSA) were similar. Aortic stiffness
and systemic vascular resistance were similar in
diabetic and nondiabetic patients.EXERCISE CAPACITY. Compared with nondiabetic
patients, diabetic patients had a lower peak VO2
(absolute and percentage predicted) (Fig. 1, Online
Table 1), despite similar effort (similar respiratory
exchange ratio). Submaximal exercise performance
also was impaired in diabetic patients as evidenced
by lower VO2 at the ventilatory anaerobic threshold
and absolute and percentage predicted 6-min walk
distance (p < 0.05 for all) (Fig.1 and Online Table 1).
Among diabetic patients, there was a trend toward a
lower peak VO2 in those treated with versus without
insulin (10.9 [9.4, 12.9] vs. 11.6 [10.1, 13.8] ml/kg/min,
p ¼ 0.07). The chronotropic index was lower, and the
prevalence of chronotropic incompetence was higher
in diabetic than nondiabetic patients, whereas peak
systolic blood pressure was similar between groups.
After adjusting for age, sex, and exercise modality,
diabetes was associated with a 2.09 ml/kg/min lower
peak VO2 (p < 0.001) (Online Table 2). After additional
sequential adjustment for factors (body mass index,
hemoglobin, and chronotropic index) that are known
to inﬂuence peak exercise performance and potential
mechanisms for the adverse effect of diabetes on
exercise performance, the relationship between dia-
betes and a lower peak VO2 was attenuated but
remained signiﬁcant (Online Table 2). Similar ﬁndings
were observed in multivariable analyses evaluating
the relationship between diabetes and 6-min walk
distance (Online Table 2).
CLINICAL OUTCOMES. Compared with nondiabetic
patients, at study enrollment, diabetic patients had
more frequently been hospitalized at least once for
heart failure over the preceding 12 months (47% vs.
28%, p ¼ 0.004) (Fig. 2A). During the 6-month study
period, diabetic patients were more likely to be
TABLE 3 Ventricular and Vascular Remodeling and Function in HFpEF Patients With and Without Diabetes
Echocardiographic Data
Non-DM (n ¼ 123) DM (n ¼ 93)
p Valuen Median (25th, 75th) n Median (25th, 75th)
LV structure
LV mass, g/ht1.7 92 63 (50, 81) 66 69 (57, 88) 0.12
LV end-diastolic dimension, cm 98 4.6 (4.2, 5.1) 66 4.6 (4.3, 5.2) 0.46
LV end-diastolic dimension/BSA, cm/m2 98 2.3 (2.1, 2.5) 66 2.1 (1.9, 2.3) 0.001
Relative wall thickness 92 0.40 (0.35, 0.45) 66 0.41 (0.38, 0.50) 0.11
LV systolic function
EF, % 123 60 (56, 65) 90 60 (55, 65) 0.47
Stress corrected mFS 78 14.2 (12.5, 16.3) 58 14.7 (12.7, 16.5) 0.50
Cardiac index, l/min/m2 102 2.5 (2.1, 2.8) 73 2.4 (2.0, 2.9) 0.78
LV diastolic function
Medial e0 113 0.06 (0.04, 0.08) 84 0.06 (0.05, 0.08) 0.64
Lateral e0 113 0.08 (0.06, 0.10) 79 0.09 (0.06, 0.11) 0.91
E/e0 (medial) 108 14.6 (11, 22) 80 18.0 (13, 25) 0.054
E/A ratio 78 1.5 (1.0, 2.3) 64 1.4 (1.0, 2.0) 0.70
Deceleration time, ms 110 185 (152, 216) 83 187 (157, 233) 0.32
LA volume, ml 90 94 (75, 121) 59 89 (70, 112) 0.34
LA volume index, ml/m2 90 47 (39, 60) 59 41 (32, 55) 0.02
Systemic and pulmonary artery function
Pulse pressure, mm Hg 118 55 (47, 68) 89 58 (48, 69) 0.32
Arterial elastance, mm Hg/ml 103 1.6 (1.3, 1.9) 75 1.4 (1.2, 1.9) 0.10
SVR, dyne/s/cm5 102 1,453 (1,150, 1,699) 73 1,322 (1,085, 1,638) 0.16
SAC, ml/mm Hg 103 1.3 (1.1, 1.7) 75 1.5 (1.1, 1.9) 0.17
PA systolic pressure, mm Hg 87 41 (34, 49) 51 43 (32, 54) 0.87
CMR data
EF, % 69 66 (60, 72) 48 65 (54, 69) 0.10
Cardiac index, l/min/m2 69 2.3 (1.9, 2.7) 46 2.4 (2.0, 2.8) 0.87
LV mass, g/ht1.7 69 50 (43, 58) 48 65 (53, 76) <0.001
LV end-diastolic volume, ml 69 110 (91, 133) 48 128 (104, 156) 0.002
LV end-diastolic volume/BSA, ml/m2 69 55 (48, 66) 48 58 (46, 69) 0.44
Aortic elastance, mm Hg/ml 69 1.6 (1.4, 1.9) 44 1.5 (1.1, 1.8) 0.17
Aortic distensibility, 103 mm Hg 54 1.1 (0.6, 1.5) 32 1.5 (0.9, 2.3) 0.051
SVR, dyne/s/cm5 69 1,488 (1,274, 1,880) 44 1,388 (1,132, 1,698) 0.10
BSA ¼ body surface area; CMR ¼ cardiac magnetic resonance; DM ¼ diabetes mellitus; EF ¼ ejection fraction; LA ¼ left atrial; LV ¼ left ventricular; mFS ¼ midwall fractional
shortening; PA ¼ pulmonary artery; SAC ¼ systemic arterial compliance; SVR ¼ systemic vascular resistance.
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545hospitalized ($1 time) for cardiac or renal causes than
nondiabetic patients (23.7% vs. 4.9%, p < 0.001)
(Fig. 2B). After adjustment for age, NYHA functional
class, and glomerular ﬁltration rate, diabetes re-
mained a signiﬁcant predictor of hospitalization for
cardiac or renal causes during the 6-month study
period (hazard ratio: 4.08, 95% conﬁdence interval:
1.60 to 10.36, p ¼ 0.003).
RESPONSE TO SILDENAFIL. There was no interac-
tion between diabetes status and treatment group
(sildenaﬁl vs. placebo) with respect to the RELAX
primary endpoint of change in peak VO2 (interaction
p ¼ 0.49) from baseline to 24 weeks or change in
6-min walk distance (interaction p ¼ 0.30). There
was also no interaction between diabetes status and
treatment group with respect to hospitalizations forcardiac or renal causes during the study period
(interaction p ¼ 0.80).
DISCUSSION
We found that in a cohort of patients with objec-
tive evidence of HFpEF and reduced exercise capac-
ity, diabetic patients had a more severe disease
phenotype characterized by more numerous comor-
bidities, increased left ventricular hypertrophy,
and increased circulating markers of vasoconstric-
tion, oxidative stress, inﬂammation, and ﬁbrosis.
Adjusting for known determinants of peak exercise
capacity, diabetic patients had a signiﬁcantly lower
peak VO2 and 6-min walk distance. Patients with
diabetes had more hospitalizations both before and
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546after study entry. These ﬁndings are consistent with a
recent novel HFpEF paradigm described by Paulus
and Tschöpe (18) and underscore that diabetic HFpEF
patients are at particularly high risk given their co-
morbidity burden and somewhat distinctive patho-
physiology. These data are relevant to the design
and interpretation of clinical trials enrolling HFpEF
patients and support the need for therapeutic stra-
tegies targeting the pathophysiology of diabetic
HFpEF patients.
Analyses from several other studies compared
diabetic with nondiabetic patients with HFpEF and
report worse outcomes in diabetic patients, in-
cluding increased mortality and hospitalizations
(3,4,13). Among patients with preserved EF (>40%)B
600.004
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trial period (B). Abbreviations as in Figure 1.in CHARM (Candesartan in Heart Failure: Assess-
ment of Reduction in Mortality and Morbidity),
diabetes was associated with a 2-fold increase in
cardiovascular death or hospitalization for heart
failure after multivariable adjustment and an 80%
increase in the hazard of all-cause mortality (3). In a
secondary analysis of the Digitalis Investigation
Group study, diabetic patients with EF >45% had an
adjusted hazard ratio of 1.68 for heart failure death
or hospitalization (4). We conﬁrm the adverse
prognostic impact of diabetes in HFpEF and extend
these previous studies in several ways. The RELAX
trial differed from other comparable studies in that
it was restricted to patients with an EF >50% and
had rigorous entry criteria to select patients with
documented cardiac limitation to exercise and
increased ﬁlling pressures by biomarker, invasive,
or echocardiographic criteria (7,8). The RELAX trial
also included a formal, detailed assessment of exer-
cise capacity, distinguishing it from these previous
studies. Finally, diabetes was also more common in
the RELAX cohort (43%) than other comparable
studies (17% to 32%), a fact that may reﬂect the entry
criteria for the RELAX study, which resulted in a
cohort with more advanced HFpEF (5–7,19).
BIOMARKER PROFILE IN HFpEF PATIENTS WITH
DIABETES. Previous studies comparing diabetic
and nondiabetic patients with HFpEF have not in-
cluded a detailed biomarker proﬁle. Using a panel
of biomarkers that evaluated multiple biological
pathways, we found that diabetic HFpEF pa-
tients have increased mediators of vasoconstriction
(endothelin-1) and ﬁbrosis (CITP, galectin-3), in-
creased oxidative stress (uric acid), and inﬂamma-
tion (C-reactive protein) and a suggestion of greater
ongoing myocardial necrosis (hs-cTnI). Diabetes
is characterized by a complex milieu of hyperin-
sulinemia, insulin resistance, hyperglycemia, and
increased circulating and intramyocardial nonester-
iﬁed fatty acids (20); these biomarker data provide
insight into the ways in which diabetes may exac-
erbate and intensify the pathophysiology of HFpEF,
which adversely affects clinical outcomes. Despite a
modestly higher LV ﬁlling pressure in diabetic pa-
tients as evidenced by a higher E/e0, there was no
difference in NT-proBNP levels, which may have
been due to a greater prevalence of obesity in the
diabetic patients.
VENTRICULAR AND VASCULAR STRUCTURE AND
FUNCTION IN DIABETIC PATIENTS WITH HFpEF. Of
the previous studies that compared diabetic and
nondiabetic patients with HFpEF (3,4,13), only 1
provided a detailed comparison of ventricular and
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547vascular structure and function (13). Consistent with
Mohammed et al. (13), we observed that systolic
function is similar between diabetic and nondiabetic
patients; indices of LV relaxation and stiffness were
also similar, whereas LV ﬁlling pressures (E/e0) ten-
ded to be higher in diabetic patients. We also
observed increased LV hypertrophy in diabetic pa-
tients. Surprisingly, left atrial volume and LV end-
diastolic dimension indexed to BSA were lower in
diabetic patients, which may reﬂect “overcorrection”
by indexing to BSA in obese patients. Resting mea-
sures of vascular function, including pulsatile and
resistive load, were similar between diabetic and
nondiabetic patients.
EXERCISE CAPACITY IN DIABETIC PATIENTS WITH
HFpEF. Diabetic patients had worse maximal and
submaximal exercise performance, which had not
been previously evaluated in patients with HFpEF.
Although we cannot determine the causative mecha-
nisms for the worse exercise performance exhibited
by diabetic patients due to the correlative study
design used, our data do provide important insights
to be further examined in future studies. We
observed signiﬁcant differences in exercise capacity
despite a lack of difference in resting systolic or dia-
stolic cardiac function (except for a trend for E/e0) or
systemic or peripheral vascular pressures or function.
In contrast, despite a similar resting HR and similar
prevalence of beta-blocker use, there was a marked
difference in the chronotropic index between diabe-
tic and nondiabetic patients. Recent studies demon-
strated the important contribution of peripheral,
noncardiac factors to exercise performance (21,22).
An increase in HR is a critical part of increasing
cardiac output and has been shown to be an im-
portant contributor to exercise capacity (21–23).
Cardiovascular autonomic neuropathy is a known
complication of diabetes, which includes diminished
exercise capacity due to impaired parasympathetic
and sympathetic responses that would normally in-
crease cardiac output and blood ﬂow to exercising
muscles (24). The withdrawal and reactivation of
vagal tone are thought to be important underlying
mechanisms for HR changes during exercise (25).
HFpEF patients have a slower HR increase, lower
peak HR, and impaired recovery (22). An attenuated
HR response to exercise is associated with increased
mortality as is slower heart recovery after exercise,
which was more common in diabetic patients (25,26).
Beyond differences in HR, there may be differences
in peripheral oxygen use that may explain, in part,
the reduced exercise capacity in diabetic compared
with nondiabetic patients with HFpEF. A signiﬁcantcontributor to reduced peak VO2 in patients with
HFpEF is reduced arteriovenous oxygen content dif-
ference, which is due to reduced O2 delivery or
reduced O2 extraction in exercising muscles (21,27).
Decreased O2 delivery may occur in diabetic patients
with HFpEF due to a greater prevalence of anemia
(a trend was seen in our data) or less vasodilator
reserve due to autonomic dysfunction, an increased
prevalence of peripheral vascular disease, or im-
paired endothelial function from oxidative stress,
inﬂammation, and vasoconstriction (consistent with
the biomarker increases we observed in diabetic
patients with HFpEF). Abnormalities in oxygen de-
livery and extraction have been observed in diabetic
patients (28,29).
Additionally, older and emerging studies demon-
strate that differences in skeletal muscle function,
composition, and strength explain important differ-
ences in exercise capacity in heart failure patients
with reduced and preserved EF (30–32). Although not
examined in this study, diabetes has been shown to
affect skeletal muscle composition and function
likely due to multiple factors including inﬂammation,
obesity, insulin resistance, fatty acid oxidation,
oxidative stress, and impaired mitochondrial func-
tion (33–35). Obesity also impairs exercise capacity
and often coexists with diabetes. Although there is
likely some overlap in the mechanisms by which
diabetes and obesity adversely affect exercise capac-
ity, we found that diabetes was still associated with
reduced exercise performance, even after controlling
for a large difference in BMI. Other studies demon-
strated that diabetes, particularly the degree of in-
sulin resistance, has a greater adverse effect on
exercise capacity than obesity (35,36).
Collectively, these data suggest that the reduced
exercise capacity of diabetic patients with HFpEF is
largely due to peripheral factors, including impaired
chronotropic reserve, reduced peripheral oxygen use,
and altered skeletal muscle function. Further studies
are needed to carefully examine these mechanisms,
as well as to evaluate the contractility and vasodilator
reserve of diabetic patients with HFpEF. Given the
more marked impairment in exercise capacity among
diabetic patients with HFpEF, it seems even more
important to encourage exercise training in these in-
dividuals, which has been shown to improve exercise
capacity and quality of life in patients with HFpEF,
largely through its effect on peripheral mechanisms
(37,38).
STUDY LIMITATIONS. Our study has several limita-
tions to consider when interpreting the results. The
enrolling sites determined the diagnosis of diabetes,
Pathophysiology  Implications and Future
Directions 
Multimorbidity
Left ventricular hypertrophy
Increased markers of fibrosis, 
oxidative stress, inflammation, 
and vasoconstriction
Elucidate peripheral
mechanisms responsible for
impaired exercise capacity
Impaired exercise capacity
due largely to peripheral
factors
Distinctive
pathophysiology
with worse
clinical outcomes
May influence the efficacy of
various therapeutic strategies
Influences the design and
interpretation of HFpEF
trials and exercise endpoints
CENTRAL ILLUSTRATION Diabetes and HFpEF: New Insights and Future Directions
Distinctive pathophysiology with worse clinical outcomes can inﬂuence future direction for these patients. HFpEF ¼ heart failure with
preserved ejection fraction.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1:
Among patients with heart failure who have pre-
served left ventricular ejection fraction, those with
diabetes have a more severe disease phenotype, more
extensive comorbidities, greater left ventricular hy-
pertrophy, and higher circulating markers of vaso-
constriction, oxidative stress, inﬂammation, and
ﬁbrosis.
COMPETENCY IN MEDICAL KNOWLEDGE 2:
More severely impaired exercise tolerance in diabetic
patients with heart failure and preserved left ven-
tricular ejection fraction is due mainly to extracardiac
factors.
TRANSLATIONAL OUTLOOK: Future studies
should be directed toward understanding the
distinctive pathophysiology and extracardiac mecha-
nisms that contribute to reduced exercise capacity in
diabetic patients who have heart failure with pre-
served left ventricular ejection fraction and address-
ing these in the design of clinical trials.
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548and it was not veriﬁed by other mechanisms. We do
not have access to data on the severity or duration
of diabetes, microvascular complications, or glucose
control. Although the detailed phenotyping of pa-
tients was a strength of the study, the relatively small
number of patients included may prevent us from
detecting signiﬁcant, smaller magnitude, differences
between the diabetic and nondiabetic patients. Fur-
ther, the small number of patients and clinical events
limits the power of our interaction analyses and our
ability to adjust for confounders in the Cox model
for hospitalization. Finally, we do not have detailed
hemodynamic and echocardiographic data at peak
exercise that would provide insight into the effect of
diabetes on cardiac and vascular reserve function.
CONCLUSIONS
In a carefully phenotyped population of patients
with HFpEF, those with diabetes were at increased
risk of hospitalization. Multimorbidity, impaired
chronotropic reserve, LV remodeling, and activation
of inﬂammatory, pro-oxidative, vasoconstrictor, and
proﬁbrotic pathways may contribute to adverse out-
comes in HFpEF patients with diabetes. The mecha-
nisms of impaired exercise performance in diabetic
patients aremultifactorial, but appear to be largely due
to peripheral factors. Our ﬁndings support the need
for therapeutic strategies targeting the distinctive
pathophysiology of diabetes in HFpEF (Central
Illustration) and have implications for the design of
clinical trials evaluating the HFpEF population.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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